MYGN Myriad Genetics Inc.

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Women’s Health, Oncology and Mental Health.

Paul J. Diaz, president and CEO at Myriad Genetics, and R. Bryan Riggsbee, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 19 at 10:30 a.m. EST.

On February 24, 2021, Mr. Riggsbee will participate in a fireside chat at the Leerink Global Healthcare Conference at 5:00 p.m. EST.

On March 2, 2021, Mr. Diaz will participate in a fireside chat at the Cowen Annual Healthcare Conference at 9:50 a.m. EST.

The presentations will be available through a live audio webcast link in the investor information section of Myriad’s website at .

About Myriad Genetics

Myriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to improving health and transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: .

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact:Jared MaxwellInvestor Contact:Scott Gleason
 (801) 505-5027 (801) 584-1143
  

 





 

 



EN
11/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE

Myriad Genetics Announces Precise MRD Clinical Data Published in The L...

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients with oligometastatic ccRCC could benefit from incorporating ultrasensitive MRD testing into t...

 PRESS RELEASE

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can S...

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when ® Psychotropic test results were available to treating clinicia...

 PRESS RELEASE

Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at . About ...

 PRESS RELEASE

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scot...

 PRESS RELEASE

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch